161 results on '"Réa D"'
Search Results
2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
3. Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer
4. The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review
5. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial
6. Agents, mechanisms and clinical features of non-scald burns in children: A prospective UK study
7. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
8. Artériopathie des membres inférieurs d’aggravation rapide chez un patient traité par nilotinib pour leucémie myéloïde chronique
9. EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial
10. MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
11. Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia
12. P701: COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TREATMENT-FREE REMISSION: DISEASE SEVERITY AND IMPACT ON TFR STATUS
13. P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
14. Time to stop operating on breast cancer patients with pathological complete response?
15. Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial
16. Test of Parity Doubling in 223Ra and 223Th
17. 142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11
18. 140 Rhinosinusitis outcomes in people with cystic fibrosis after 6 months of elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study
19. Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation
20. Interpretation of the 3- to 4-Micron Infrared Spectrum of Mars
21. Two Novel Assays of Alloantibody-Secreting Cells Demonstrating Resistance to Desensitization With IVIG and rATG
22. Real-world Experience within Standard NHS Use of Traztuzumab Deruxtecan as Late Line Therapy for Advanced HER-2-positive Breast Cancer
23. Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts
24. Arrêt du traitement par inhibiteurs de tyrosine-kinase
25. The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting
26. Chronic neutrophilic leukemia: A study of four cases
27. 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
28. Interleukin-2, Interferon-α and 5-Fluorouracil Immunotherapy for Metastatic Renal Cell Carcinoma: The All Ireland Experience
29. Mars: The Origin of the 3.58- and 3.69-Micron Minima in the Infrared Spectra
30. Mars: Influence of Topography on Formation of Temporary Bright Patches
31. S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY
32. S883 COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY
33. Low-cost PM2.5 sensors can help identify driving factors of poor air quality and benefit communities
34. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
35. Report of the Group Studying: Inferences from the Marine Sedimentary Record
36. Observation of the Tailwaves of Mouse Spermatozoa
37. The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research
38. The Role of Infrared Spectroscopy in the Biological Exploration of Mars
39. 1894P - Cardioprotective and anti-inflammatory effects of empagliflozin during treatment with doxorubicin: A cellular and preclinical study
40. 1306P - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models
41. The SMALL Trial: A Big Change for Small Breast Cancers
42. The Use of Pertuzumab for Breast Cancer Patients in the Neoadjuvant Setting Presenting to a Tertiary Centre
43. 313P - Eribulin in metastatic breast cancer the UK experience: A multi-centre retrospective 577 patient study
44. Optical Studies on the Phase Transitions in YBaMn2O6 Single Crystals
45. Inappropriate dispensation of antimicrobials in pharmacies in Santa Cruz de la Sierra, Bolivia
46. Hmga2 Cooperates with Either p27 Deficiency or Cdk4R24C Mutation in Pituitary Tumourigenesis
47. Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia
48. P105 The MAGIC survey in HR+, HER2− breast cancer (BC): when might multigene assays be of value?
49. P059 Ranolazine administered after trastuzumab treatment prevents cardiotoxicity in mice
50. Hypercholestérolémie induite précocement par nilotinib, un inhibiteur de tyrosine kinase de seconde génération, chez des patients traités pour leucémie myéloïde chronique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.